[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380534-105":59,"doc-detail-380534-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prognostic-value-of-pretreatment-inflammatory-markers-in-localised-prostate-cancer-before-radical-prostatectomy-abstract","Prognostic value of pretreatment inflammatory markers in localised prostate cancer before radical prostatectomy - Abstract","","The study evaluates whether clinically established pretreatment inflammatory markers predict prognosis in patients with localised prostate cancer prior to radical prostatectomy. A prospective cohort of 641 men was followed for a median of 2.85 years, with associations tested using logistic and Cox regression. Pretreatment markers showed no significant links to adverse pathology or biochemical recurrence-free survival, while known risk factors correlated with shorter BRFS.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-value-of-pretreatment-inflammatory-markers-in-localised-prostate-cancer-before-radical-prostatectomy-abstract/380534/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-value-of-pretreatment-inflammatory-markers-in-localised-prostate-cancer-before-radical-prostatectomy-abstract/380534.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this study?","Question",{"text":112,"@type":113},"To evaluate the prognostic role of clinically established pretreatment inflammatory markers in patients with localised prostate cancer before radical prostatectomy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and outcomes assessed?",{"text":117,"@type":113},"A prospective cohort of 641 men was followed for a median of 2.85 years, and logistic and Cox regression analyses were used to test associations with tumor characteristics and biochemical recurrence-free survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Did pretreatment inflammatory markers relate to worse outcomes?",{"text":121,"@type":113},"No. The study found no statistically relevant association between pretreatment inflammatory markers and worse pathological features or shorter biochemical recurrence-free survival (all p > 0.05).",{"name":123,"@type":110,"acceptedAnswer":124},"Which factors were associated with shorter biochemical recurrence-free survival?",{"text":125,"@type":113},"Known risk factors—tumor grade, tumor stage, nodal positivity, and positive surgical margins—were associated with shorter BRFS (all p \u003C 0.0001).","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},380534,1790466567,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","World Journal of Urology (2023) 41:2693–2698  \n[https://doi.org/10.1007/s00345-023-04569-8](https://doi.org/10.1007/s00345-023-04569-8)  \nPrognostic value of pretreatment inflammatory markers in localised prostate cancer before radical prostatectomy  \nJosias Bastian Grogg1 · Gianluca Rizzi1 · Jana Gadient1 · Marian Severin Wettstein1 · Andres Affentranger1 · Christian Daniel Fankhauser1 · Daniel Eberli1 · Cédric Poyet1  \nReceived: 17 May 2023 / Accepted: 6 August 2023 / Published online: 25 September 2023 © The Author(s) 2023  \nAbstract  \nPurpose There is growing evidence of an association between inflammatory processes and cancer development and progression. In different solid tumor entities, a pronounced inflammatory response is associated with worse oncological outcome. In this study, we aim to evaluate the prognostic role of clinically established pretreatment inflammatory markers in patients with localised prostate cancer (PCa) before radical prostatectomy (RP) .  \nMethods A total of 641 men met our inclusion criteria and were followed prospectively for a median of 2.85 years. Univariable logistic and Cox regression analysis were performed to analyse associations between preoperative inflammatory markers and tumor characteristics, and biochemical recurrence free survival (BRFS) .  \nResults Median age at RP was 64 years. Gleason Score (GS) 7a (263, 41%) was the most prevalent histology, whereas highrisk PCa (≥ GS 8) was present in 156 (24%) patients. Lympho-nodal metastasis and positive surgical margin (PSM) were detected in 69 (11%) and 180 (28%) patients, respectively. No statistically relevant association could be shown between pretreatment inflammatory markers with worse pathological features like higher tumor stage or grade, nodal positive disease or PSM (for all p >0.05) . Additionally, pretreatment inflammatory markers were not associated with a shorter BRFS (p >0.05). Known risk factors (tumor grade, tumor stage, nodal positivity and positive surgical margins) were all associated with a shorter BRFS (for allp \u003C 0.0001) .  \nConclusion In this large prospective cohort, preoperative inflammatory markers were not associated with worse outcome.  \nKeywords Urology · Oncology · Prostate cancer · Inflammatory markers · Prospective cohort  \nAbbreviations  \nBCR Biochemical recurrence  \nBPH Benign prostatic hyperplasia  \nBRFS Biochemical recurrence free survival  \nCI Confidence interval  \nCRP C-reactive protein  \nCSS Cancer specific survival  \nGS Gleason Score  \nHR Hazard ratio  \nmCRPC Metastatic castration resistant prostate cancer  \nNLR Neutrophil-to-lymphocyte ratio  \nOS Overall survival  \n* Josias Bastian Grogg [josias.grogg@usz.ch](josias.grogg@usz.ch)  \n1 Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091 Zurich, Switzerland  \nPCa  \nPLR  \nPSA  \nPSM  \nRP  \nWHO/ISUP  \nProstate cancer  \nPlatelet-to-lymphocyte ratio Prostate specific antigen Positive surgical margins Radical prostatectomy  \nWorld Health Organization/International Society of Urologic Pathologists  \nIntroduction  \nProstate cancer (PCa) is the second most diagnosed cancer in men and accounts for approximately 7% of all cancer deaths in males. Worldwide, each year approximately 1.3 million men are diagnosed with PCa and it is the 5th leading cause of cancer death in men, nearly 360,000 men per year die because of it [3] .  \nThe association of inflammation and cancer is not new but the exact mechanisms in cancer development are not  \nfully understood yet. In 1863 already, Virchow described cancer development through inflammatory processes [2] . Approximately 15% of all oncologic diseases are linked to chronic inflammation and/or infection [9] . The association of different inflammatory markers and carcinogenesis and oncological outcome has been investigated thoroughly. Oneof the most studied inflammatory marker is the neutrophilto-lymphocyte ratio (NLR) . The association of a high NLR with worse oncological o","cbCaip0BBztLcB5u","https://ap.wps.com/l/cbCaip0BBztLcB5u","pdf",727786,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Abbreviations\n# Introduction\n# Material and methods\n## Study design","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To evaluate the prognostic role of clinically established pretreatment inflammatory markers in patients with localised prostate cancer before radical prostatectomy.\"},{\"question\":\"How were patients and outcomes assessed?\",\"answer\":\"A prospective cohort of 641 men was followed for a median of 2.85 years, and logistic and Cox regression analyses were used to test associations with tumor characteristics and biochemical recurrence-free survival.\"},{\"question\":\"Did pretreatment inflammatory markers relate to worse outcomes?\",\"answer\":\"No. The study found no statistically relevant association between pretreatment inflammatory markers and worse pathological features or shorter biochemical recurrence-free survival (all p \\u003e 0.05).\"},{\"question\":\"Which factors were associated with shorter biochemical recurrence-free survival?\",\"answer\":\"Known risk factors—tumor grade, tumor stage, nodal positivity, and positive surgical margins—were associated with shorter BRFS (all p \\u003c 0.0001).\"}]","Prognostic value of pretreatment inflammatory markers in localised prostate cancer before radical prostatectomy - Abstract | PDF",1790240571,15]